Please note. Investigational: not approved by the FDA. Information is for clinical and research awareness only. Not a recommendation to use.
No perspectives yet — be the first!
Be the first verified clinician to share a view on Zadavotide.
100% anonymous · NPI-verifiedFDA status last checked Nov 11, 2026
In Phase 3 clinical trials led by AstraZeneca, studied for metastatic castration-resistant prostate cancer, oligometastatic prostate adenocarcinoma and recurrent prostate adenocarcinoma. Not yet approved by the FDA.
Zadavotide
Not approved by the FDA. Being tested in clinical trials (furthest: Phase 3).
We have not yet attached proof for an evidence level.
How it works. Proven facts and ideas still being studied are kept apart.
Not yet reviewed.
We have not yet attached proof for an evidence level.
Not yet reviewed.
Not FDA-approved. In clinical trials (highest phase: Phase 3); 1 trial(s) listed on ClinicalTrials.gov, led by AstraZeneca.
Last verified: Nov 11, 2026
Share your pre-launch perspective on Zadavotide and help peers make informed prescribing decisions.
Your 45-second perspective helps thousands of colleagues.
Your real-world insights guide colleagues
Your identity stays private — only specialty/region shown
Compare your perspective to specialty peers
